Abstract
To assess the efficacy, safety, and tolerability of acarbose versus placebo during a 24-week treatment period in Asian type 2 diabetic patients with dietary failure. After a 6-week screening period, 126 multiethnic Asian type 2 diabetic patients (64 men, 62 women; mean age +/- SD, 53.4 +/- 10 years) were randomized to receive acarbose (n = 63) or placebo (n = 63). The dosage was increased from 50 mg t.i.d. at week 0 to 100 mg t.i.d. at week 4. Patients were then followed up at weeks 10, 16, and 24. At each visit, body weight, blood pressure, and metabolic indexes were measured. At weeks 0 and 24, fasting plasma glucose and insulin were measured before and 1 h after the administration of an individually tailored breakfast. Using the intention-to-treat analysis, there were greater reductions in (mean [95% CI]) HbA1c (-0.70 [-1.00 to -0.39] vs. -0.27% [-0.54 to 0]; P = 0.04), fasting plasma glucose (-0.37 [-0.75 to 0.02] vs. 0.41 mmol/l [-0.08 to 0.90]; P = 0.017) and 1-h plasma glucose (-0.77 [-1.44 to -0.10] vs. 0.65 mmol/l [-0.07 to 1.36]; P = 0.05) in the acarbose group compared with the placebo group. With acarbose treatment, 78% of patients achieved an HbAlc < 8% compared with 56% in the placebo group (P = 0.003). There was ...Continue Reading
Citations
Apr 23, 2003·Diabetes Research and Clinical Practice·Chii-Min HwuUNKNOWN Asian Acarbose Study Group
Sep 11, 2003·Diabetes Research and Clinical Practice·Chang-Yu PanHua Cheng
Jun 18, 2003·Journal of Diabetes and Its Complications·Boniface J LinUNKNOWN Writing Group for the Asian Study of Acarbose with Sulfonylureas
Aug 25, 2001·Diabetes, Obesity & Metabolism·J M CarrascosaJ Satrústegui
Oct 18, 2013·Diabetes Technology & Therapeutics·Satish K GargViral N Shah
Nov 16, 2013·PloS One·Xiaoling CaiLinong Ji
Mar 20, 2012·ClinicoEconomics and Outcomes Research : CEOR·Christian Díaz de León-CastañedaJuan Manuel Martínez-Núñez
Apr 18, 2003·Drugs·André J Scheen
Dec 14, 2006·Clinical Drug Investigation·Yi-Jen HungHarald Landen
May 18, 2007·Clinical Drug Investigation·Chang-Yu Pan, Harald Landen
Dec 31, 2015·Current Medical Research and Opinion·Jinping ZhangWenying Yang
Mar 5, 2016·Journal of Diabetes and Its Complications·Oliver SchnellWladyslaw Grzeszczak
Apr 23, 2013·Clinical Therapeutics·Qibo ZhuNanwei Tong
Nov 17, 2015·Postgraduate Medicine·Tamer Yacoub
Nov 26, 2009·Bioorganic & Medicinal Chemistry·B China RajuK Madhusudana
May 24, 2014·International Journal of Clinical Practice·Y LiN Tong
Jul 22, 2014·Diabetes/metabolism Research and Reviews·Jianping WengSanjay Kalra
Sep 15, 2014·The Lancet. Diabetes & Endocrinology·Wenying Yang, Jianping Weng
Jan 22, 2011·Diabetes Research and Clinical Practice·Chunlin LiBirgit Schmidt
Jul 30, 2002·Neonatal Network : NN·C W Jones
May 12, 2015·PloS One·Shuyan GuHengjin Dong
Jul 5, 2016·The Lancet. Diabetes & Endocrinology·Weiping Jia
Feb 28, 2001·Diabetes, Obesity & Metabolism·J C López-AlvarengaJ A Rull-Rodrigo
Nov 3, 2016·PloS One·Shuyan GuHengjin Dong
Dec 13, 2006·Diabetes & Vascular Disease Research : Official Journal of the International Society of Diabetes and Vascular Disease·Ramzi A Ajjan, Peter J Grant
Apr 23, 2005·The Cochrane Database of Systematic Reviews·F A Van de LaarC Van Weel
Jul 8, 2017·Journal of Diabetes Investigation·Xueying GaoLinong Ji
Aug 11, 2015·Expert Opinion on Pharmacotherapy·Shashank R JoshiRahul Rathod
Dec 24, 2004·Diabetes Care·Floris A van de LaarChris van Weel
Sep 19, 2020·PLoS Medicine·Calvin KeAndrea Luk
Nov 17, 2020·BMC Medicine·Chu LinLinong Ji